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Abstract
Although most classical Hodgkin lymphoma patients are cured, a significant minority fail after primary therapy and may die
as result of their disease. To date, there is no consensus on biological markers that add value to usual parameters (which
comprise the International Prognostic Score) used at diagnosis to predict outcome. We evaluated 59 patients (18 with
primary refractory or early relapse disease and 41 responders) for bcl2, Ki67, CD20, TiA1 and c-kit expression by semi-
quantitative immunohistochemical study and correlated the results with the response to treatment. The results showed
that expression of bcl2 and CD20 in Hodgkin and Reed Sternberg cells, and expression of TiA1 in micro-environmental
lymphocytes, and c-kit positive mast cells in microenvironment, were independent prognostic markers. These novel cHL
markers could be used in association with clinical parameters to identify newly diagnosed patients with favorable or
unfavorable prognosis and to better tailor treatment for different risk groups.
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Introduction
Classical Hodgkin lymphoma (cHL) is a highly curable
lymphoma and about 80% of patients can be cured with modern
treatment strategies [1,2]. In spite of great clinical progress, a
significant minority of cHL experiences treatment failure after
primary chemotherapy including a first line of anthracyclin-based
regimen [2,5]. Patients with refractory cHL represent 5 to 10% of
cHL. Many of these patients have a poor overall survival of 26%
at 5 years [6]. A better biological characterization of such primary
refractory patients might allow the use of targeted therapeutic
strategies earlier during the course of the disease [1,7]. Most
prognostic score systems used to date for advanced stage of the
disease, including the International Prognostic Score (IPS), which
incorporates seven clinical and laboratory parameters, failed to
accurately identify patients with unfavorable responses to therapy
[1,7–9] . Therefore, current attempts to identify high risk patients
who may benefit of novel therapies have not proven to be
successful to date [10–13]. Several markers such as serum levels of
soluble CD30 [1,14] and some interleukins [15,16] might provide
additional prognostic information to the clinical models. Different
studies reported a correlation between markers of cell activation
and/or differentiation, cell cycle and apoptosis deregulation,
Epstein Barr Virus (EBV) detection in the neoplastic Hodgkin and
Reed Sternberg (H/RS) cells and the clinical outcome of cHL
patients [17,18]. A peculiar feature of Hodgkin disease is that
neoplastic cells constitute less than 1% of the cellular population
of HL-involved tissues since H/RS cells are interspersed among a
heterogeneous population of non malignant reactive cells [19].
Several studies have documented that H/RS cells are highly
interactive with this microenvironment through direct cell
contacts and production of various cytokines and chemokines
[14,16,20].
To further evaluate the prognostic significance of new biological
markers in cHL, we compared the expression of bcl2, Ki67 and
CD20 expression in H/RS cells of refractory and early relapse
patients to that of responder patients. In addition, we compared
the expression of TiA1 in surrounding T lymphocytes as a putative
marker of an anti-tumoral immune response [21–23] in both
groups of patients. We also looked at the expression of c-kit to
evaluate the presence of mastocytes, which might modify the
behaviour of cHL [24,25]. These results were analyzed statistically
in conjonction with clinical and laboratory parameters and were
correlated with treatment response.
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Patients
A total of 65 patients were retrospectively collected from 1997
to 2004 in 2 hematology centres (Necker Hospital and Gustave
Roussy Institute, Paris France): all available poor prognosis
patients were first identified (18 patients with primary refractory
disease or early relapse) and the control group (47 responders) was
randomly selected. Patients were eligible for this study if they
fulfilled the following criteria: (1) diagnosis based on a lymph node
biopsy (or another organ) performed before any treatment; (2)
paraffin-embedded formalin-fixed tissue blocks from the diagnosis
lymph node (or another organ) available for immunohistochemical
studies; (3) a minimum follow-up of 2 years and (4) a negative
human immunodeficiency virus (HIV) serology. Our clinical trial
has been performed after having been approved by the authors’
institutional review board of the 2 hospitals involved in this study.
The data of patients were analyzed anonymously and all clinical
investigation has been conducted according to the principles
expressed in the Declaration of Helsinki.
Patients received conventional chemotherapy-based treatments
[(MOPP (mechlorethamine, vincristine, procarbazine, and pred-
nisone), ABVD (doxorubicine, bleomycine, vinblastine, and
dacarbazine) or the combination of both or BEACOPP (bleomy-
cine, etoposide, doxorubicine, cyclophosphamide, vincristine,
procarbazine, prednisone)] and radiotherapy in stages I and II.
Treatment decisions were not based on molecular and/or
immunohistochemical features.
Records of patients were reviewed by two hematologists (BD
and VR). Clinical, analytical, therapeutic and follow-up data were
collected in a data base including age, sex, Ann Arbor staging, B
symptoms (weight loss, fever, drenching sweat), histologic type,
number of lymph nodes and extranodal sites, erythrocyte
sedimentation rate, serum level of lactate deshydrogenase,
albumin, b2-microglobulin, hemoglobin concentration, lympho-
cytopenia, response to therapy (complete response versus treat-
ment failure), overall survival from time of diagnosis (or beginning
of treatment), and for responding patients, relapse free survival
from the end of therapy. Complete remission was defined as the
resolution of clinical and radiological evidence of disease for a
minimum of 4 weeks. Primary refractory disease was defined as an
absence of treatment response or the evidence of disease
progression within the first 3 months period after the end of
treatment. Early relapse was defined as disease progression in the
first year after diagnosis. Patients were considered as responders
when they remained in complete response for at least one year
after diagnosis. All data were checked for validity and coherence.
Errors and missing values were reported to the contributors and
investigators for correction or confirmation.
Six cases were excluded because of lack of tissue samples in
three of them and unsatisfactory immunohistochemical staining in
3 other cases. Thus, 59 out of the 65 cases collected were
considered eligible for the final statistical analysis: 18 patients with
primary refractory disease or early relapse and 41 responders.
Pathological and immunohistochemical procedures
All cases were reviewed independently by one hematopathol-
ogist (DC) who was blinded as to treatment response. Diagnosis
confirmation of cHL and histological subclassification were
performed on slides stained with hematoxylin and eosin, Giemsa
and Gordon-Sweet stains, following the Rye classification in four
main types: lymphocyte predominance, nodular sclerosis, mixed
cellularity and lymphocyte depletion. Priority in the diagnosis was
conferred to the morphological study.
Tissue samples were fixed in 10% formalin and embedded in
paraffin. Most of them were lymph nodes, 3 were extra nodal
specimens in the absence of adenopathy (liver, spleen and bone
tissue). Immunohistochemistry was performed using automated
immunohistochemical stainers (Techmate 500 Dako, Dako
Cytomation). Tissue sections were incubated with the following
antibodies: CD20/L26, CD3/F7.2.38, Ki67/MiB1, bcl2/124 (all
from Dako Cytomation), c-kit/CD117, and TiA1/2G9 (from
Immunotech). All of them are mouse monoclonal antibodies
except c-kit, which is a rabbit polyclonal antibody. After
incubation, immunodetection was performed with the ChemMate
Dako EnVision detection kit (Dako Cytomation) employing
Peroxidase/Diaminobenzidine. Other cells in the sections served
as internal controls for each antibody.
Analysis of sections was assessed using a semi-quantitative
method which differed depending on the antibody used. For
CD20 and CD3 antibodies, the number of negative or positive H/
RS cells was evaluated. In positive cases defined by the presence
of at least 10% of antigen expressing cells, the number of stained
H/RS cells among 200 randomly selected H/RS cells was
assessed. For Ki67 and bcl2 antibodies the number of stained H/
RS cells on 200 randomly selected H/RS cells was evaluated. The
number of lymphocytes stained with TiA1 antibody was assessed
on 10 fields randomly selected per high power field (hpf) (6400).
For c-kit antibody, the number of mast cells was evaluated on hpf
(6400) following the same process than that with TiA1 antibody
(Figure 1).
Statistical analyses
Patient characteristics were compared using the Fisher exact test
for categorical variables and the Wilcoxon test for continuous
variables in order to identify factors that might significantly
influence survival and initial response to treatment. Only cases
with all of the required data were selected for statistical analysis.
The analysis was thus performed in 59 patients from the initial
group of 65 patients. For this initial analysis these tests were used
to compare the means of the continuous variables between
patients. Results were expressed as median (percentile 25–75%
except for CD20 since in this case the exact number of positive
cells has not been determined when it was under 10%). For these
results to be applied to individual cases, a specific analysis based on
cut-off levels has been required.
An univariate analysis was performed for each clinical variable
and for the tumor expression in tissue of the five analyzed markers
(Ki67, CD20, bcl-2, c-kit and TiA1), first with continuous variable
and then with binary variable.
A multivariate analysis was performed to identify the factors
that might be of independent significance in influencing overall
survival and failure to achieve complete response. Variables
included were: age (over or under 45 years), Ann Arbor stage (I–II,
versus III–IV), B symptoms (present or absent), gender, number of
lymph nodes involved (over or under 3), erythrocyte sedimentation
rate (over or under 30), albumin (over or under 40 gr/l),
hemoglobin rate (over or under 10.5 g/dl), LDH (.1N or N),
lymphocytes (over or under 600), CD20, bcl-2, TiA1 and c-kit
(with continuous variable and then binary variables). Immunohis-
tochemical markers were included in a logistic-regression model,
to provide adjusted tests of the relationship between each
immunohistochemical marker and the refractory status.
All tests were two-sided and p-values of 0.05 or less were
considered as statistically significant. Statistical analyses were
conducted with the R software, version 2.0.
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PLoS ONE | www.plosone.org 2 July 2009 | Volume 4 | Issue 7 | e6341Figure 1. A & B: Rare or no (arrows) H/RS cells stained with CD20 in refractory cHL (A) compared to the overexpression of CD20 on H/RS cells in a
respondercHL (arrows)(B) (originalmagnification6400).C&D : NumerousH/RS cellsstained with bcl2 in a refractorycHL (arrows)(C) comparingtorare
cells in a responder case (arrow)(D) (original magnification6400). E&F : TiA1 expressed on numerous small lymphocytes in a refractory cHL (arrows) (E)
andless frequent cellsstainedwith this antibody ina respondercHL (arrows)(F) (original magnification6400). G&H : c-kitstained frequentmast cells in
a refractory cHL (arrows) (G) compared to rare mast cells expressing c-kit in a responder cHL (arrows) (H) (original magnification 6400).
doi:10.1371/journal.pone.0006341.g001
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Clinical and usual Biological findings
A total of 59 patients randomly selected in the 2 centres formed
the basis of the study distributed among 18 refractory or early
relapse cHL and 41 responders to treatment. Their clinical
features and the results of the univariate analysis are summarized
in Table 1.
Initial diagnosis of cHL was confirmed by histological analysis of
a lymph node in 56 cases or an extra nodal site in 3 cases. Most
patients presented a nodular sclerosis subtype of cHL regardless
whether they were refractory (17/18cases, 94.5%) or responders
(37/41cases, 90%). The other histological type was mixed
cellularity for 5 cases.
In univariate analysis the group of responder patients and that
of those with early relapse or primary refractory disease were
comparable according to the following characteristics: age, sex,
histopathological type, stage and number of involved lymph nodes,
albumin, hemoglobin concentration and lymphocytes. However,
patients with refractory or early relapse cHL showed significantly
more B symptoms (p=0.02), higher sedimentation rate (p=0.008)
and LDH levels (p=0.001).
Tumoral cells characteristics
The expression of CD20 in Hodgkin or Reed-Sternberg (H/RS)
cells was heterogeneous and significantly less frequent in refractory
or early relapse cHL (15% of HRS positive cells) than in
responders (34% of HRS positive cells) (p=0.03) (Figure 1A).
Thus, CD20 seems to be overexpressed on H/RS cells of
responding patients. The median value of bcl2 positive H/RS
represented 51% of HRS cells in refractory or early relapse
patients and only 12% of H/RS cells of responders. This
difference was statistically significant (p=0.01). (Figure 1B).
Numerous small lymphocytes were stained with CD3 (no
difference between both groups) but this antibody was negative on
H/RS cells in our series (data not shown). No difference was found
between Ki67 expression in responders and in refractory cHL
since H/RS cells were diffusely stained with Ki67 in both groups
(.80%).
Non neoplastic tumor-infiltrating cells characteristics
Refractory or early relapse cHL had significantly higher
numbers of infiltrating cytotoxic TiA1+ small lymphocytes
(median=42/hpf) than chemosensitive ones (median=21/hpf)
(p=0.0005) (Figure1C). TiA1 positive cells were scattered in the
lymphoma or in foci. C-kit antibody (CD117) was negative on H/
RS cells but allowed to evaluate the number of mast cells stained,
which was significantly higher in refractory cHL (median=9/hpf)
than in responders (median=3.8/hpf)(p=0.001) (Figure 1D).
Thus, TiA1+ lymphocytes and mast cells are more numerous in
the non tumoral background of refractory or early relapse cHL
than in responding patients.
In summary, in the univariate statistical analysis immunohisto-
chemical markers including CD20, bcl2, TiA1 and c-kit were
significantly different in refractory or early relapse and responders
patients and were correlated with the treatment response.
Multivariate statistical analysis
Multivariate statistical analysis including bcl2, TiA1, c-kit and
CD20 markers (with continuous variable) revealed that only low
CD20 (p=0.04), (or,30% with binary variable (p=0.04)), high
bcl2 (p=0.01)( .40% with binary variable (p=0.008)), and high
TiA1 (p=0.003)( .30% with binary variable (p=0.002)) expres-
sion remained independently associated with the refractory status
of cHL (Table 2).
We also analyzed relationships between molecular markers and
clinical and common biological parameters. A significant link was
found between the number of mast cells assessed by ckit expression
and B symptoms in the refractory cHL (p=0.017). This link was
not present in the responders (p=0.76) (data not shown).
Discussion
This retropective study of 59 patients presenting either
refractory and early relapse or responding classical Hodgkin
lymphoma provides evidence that new immunohistochemical
markers taking into account apoptosis markers of tumoral cells
as well as surrounding microenvironment could be predictive of
response to treatment in cHL patients.
Some markers based on the presumed pathogenesis of cHL
have been reported as having a prognostic value for patients with
cHL but there is no consensus on biologic markers that add
prognostic value to the clinical parameters [1,7,18,21,22].
Moreover, none of them was studied on refractory patients
compared to responding patients.
The pathogenesis of cHL remains poorly understood and single-
cell techniques have proven that H/RS cells are derived from
germinal center B cells [26,27] but lack immunoglobulin
expression. However, although normal germinal center B cells
that lack functional high affinity antibody undergo apoptosis
within germinal center, H/RS cells may escape this programmed
cell death [28,29]. Thus alteration of apoptosis regulators
expression in H/RS cells [7,30] may prevent apoptosis caused
by the absence of the functional B-cell receptor and may explain
resistance to treatment [31,32]. To test this hypothesis we have
quantified the percentage of H/RS cells that expressed the anti-
apoptotic bcl2 protein. We found that bcl2 was highly expressed in
HRS cells of refractory or early relapse cHL and was an
independent factor in multivariate analysis (p=0.01). This finding
extends in the refractory population the results recently reported
by Smolewski & al and Garcia & al that showed a shorter survival
in patients with high expression of bcl2 [17].
Although H/RS cells originate from germinal center B cells, the
classical B-cell marker CD20 is expressed in only 20–30% of cHL
[27,33]. The prognostic significance of CD20 expression in cHL is
controversial and a matter of ongoing debate [33–37]. Indeed, some
studies found no significant association between CD20 expression in
H/RScellsand theoutcomeofcHL[34,36],whereasothersreported a
worse clinical outcome in CD20-positive patients [35,37]. Surprisingly,
we found that the lack of CD20 expression was associated with
refractorydiseaseandremainedsignificantinmultivariateanalysis.Our
results on refractory cHL are close to those of Tzankov & al [33] who
reported a significantly higher frequency of disease relapses in the
CD20 negative group compared to the CD20 positive cHL with a
followupof12yearsandacutoffof10%ofcellsexpressingthisantigen.
The reason for a significant higher CD20 expression in H/RS cells in
responders compared to that of refractory cHL is unknown. CD20
resembles a Ca2+ion channel and is involved in signal transduction for
B-cell differentiation and proliferation. Tzankov [33] suggested that an
increase of Ca2+ permeability in H/RS cells along with chemotherapy
and/or radiotherapy could decrease apoptotic resistance or even
activate programmed cell death, as it does in other lymphomas [38]. It
is also possible that CD20 expression could be a marker of a different
gene expression program associated with a better response to treatment
and then with a better outcome [28,29]. Moreover it raises the question
of whether there is a correlation between this expression in H/RS cells
and the response to anti-CD20 therapy in cHL [34,39]. Indeed, recent
Prognosis Refractory Hodgkin
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Number of pts n=59
Primary Refractory or
early relapse n=18 Responders n=41 Wilcoxon p
Sex
Female 28 11 17
Male 31 7 24 0.2
Age, years
,45 y 44 16 28
.or=45 y 15 2 13 0.1
Stage
I–II 44 12 32
III–IV 15 6 9 0.5
Histological Sbtype
Nodular sclerosis 54 17 37
Others 5 1 4
B symptoms
No 31 5 26
Yes 25 13 15 0.02
Sedimentation Rate
.30 37 16 21
,or=30 22 2 20 0.008
Albumin
.or=40 41 11 30
,40 18 7 11 0.7
Hemoglobin level
.or=10.5 45 13 32
,10.5 14 5 9 0.4
LDH level
,or N 46 9 37
.N 13 9 4 0.001
Lymphocytes
.or=600 53 14 39
,600 6 4 2 0.08
First Line Therapy
ABVD 47 14 33
EBVP 8 3 5
BEACOPP 3 1 2
IHC markers C.V: median (range 25–75%)
% HRS CD20+ 15 34 0.03
% HRS bcl2 high 51 (5.75–75.75) 12 (7.5–27.5) 0.01
Number of L TiA1+ 42 (25.75–50.75) 21 (14–30) 0.0005
Number of MC ckit+ 9 (5–13.5) 3.8 (2.4–6) 0.001
Binary variable: nber of patients(%)
HRS CD20.30% 2 (11%) 17 (41%) 0.03
HRS bcl2.40% 12 (66%) 8 (19%) 0.0008
L TiA1+.30 12 (66%) 12 (29%) 0.01
Mast cells.6 12 (66%) 12 (29%) 0.01
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expression of CD20 molecules on distinct histological types of
lymphoma correlates with rituximab efficacy [39,40].
High proliferation index (Ki67) is described as an adverse
prognostic factor in non HL. Morente & al [41] reported the same
results in a study of 140 patients with HL and showed that a high
proliferation index influenced lower overall survival and failure to
achieve complete remission. In our series, however, there was no
significant difference of proliferation index between responder
cHL and refractory patients since Ki67 was highly expressed in
both groups (data not shown).
Hodgkin lymphoma is characterized by a minority of tumour
cells surrounded by a large amount of non-neoplastic cells [19].
Knowledge about the biology of the disease particularly the
interaction between H/RS cells and the surrounding cells is
essential in order to improve its diagnosis and treatment. Although
the composition of the infiltrate of the background is heteroge-
neous, most cells are CD4+ lymphocytes. Recent studies of HL
have shown that infiltrating lymphocytes in cHL lymph nodes are
predominantly CD4+, CD25+ regulatory T cells which have
suppressive functions and induce a profoundly immunosuppressive
environment [21–23]. This finding suggests that the presence of
regulatory T cells in the reactive background may explain the
inhibition of the antitumoral host immune response observed in
cHL [23]. Our study aimed at assessing the relevance of cytotoxic
T cells (CTL) present in the background of cHL samples in the
response to treatment. We found that a high proportion of TiA1+
cells in the infiltrate represents a prognostic factor that negatively
influenced the response to treatment. Indeed, patients who were
refractory to treatment showed a significant higher count of TiA1+
cells in the samples studied compared to responding cHL
(p=0.0005). Furthermore, this marker remains an independant
factor predictive of a poor response to treatment in a multivariate
analysis (p=0.003). This result is similar to the study of Lejeune et
al who reported more TiA1+ cells (and a lower proportion of
FOXP3+ cells) in the samples of patients who relapsed compared
to the features at the time of diagnosis [21,22]. This finding
suggests that primary refractory cHL shows the same pattern of
anti-tumoral host immune response as the relapsing one. It could
seem inappropriate that a lot of CTL in the background of cHL be
associated with a worse response to treatment of these patients.
The hypothesis for explaining these results could be the
consequence of defective CTL against H/RS cells that may
paradoxically provide survival factors. It remains however to be
determined by which mechanisms H/RS or other infiltrating cells
inhibit CTL function.
Among the reactive cells which surround H/RS cells, mast
cells are important since they are CD30ligand (L)-positive and
they activate H/RS cells in vitro through CD30-CD30L
interaction but also through soluble factors like interleukin 8, 9
or 13 [24,25,42]. Mast cells are the predominant CD30L-
positive cells and play a role in many inflammatory disorders and
have important immunoregulatory functions through cytokines
and accessory molecules expression [24]. They are often present
in tumors but their role in cHL has rarely been explored [25,43].
As reported by Molin & al [43], we found that a high number of
mast cells expressing c-kit receptor had a clinical importance in
the response to treatment. Indeed, for Molin & al [43],
significant mast cell infiltration was associated with a worse
relapse-free survival and in our series it was much more frequent
in refractory or early relapse cHL than in responding patients
(p=0.001). The CD30L present on mast cells is functionnally
active and can provide stimulatory signals to H/RS cells [24].
Thus, mast cells that constitute an important portion of the
infiltrating reactive cells may contribute to tumor progression in
cHL. Mast cells might be specifically attracted to the tumor area
by chemokines produced by H/RS cells and studies revealed
several chemokines in HL lines among which CCL5 (RANTES)
[24,43,44]. This chemokine could be a good candidate
responsible to mast cell attraction into tumor tissue in cHL.
Knowing that mast cells express c-kit receptor and that, during
our experiment they were significantly more numerous in
refractory cHL than in responders, drugs inhibiting the tyrosine
kinase activity of ckit, like Imatinib (Gleevec), in combination
with chemotherapy might have therapeutic value in refractory c-
HL (45). Beside this effect on cHL prognosis the presence of mast
cells is correlated with B symptoms. This finding may be related
t oc y t o k i n e sa n dm e d i a t o r sr e l ease by activated mast cells
[45,46]. To confirm this hypothesis, in future prospective studies
it would be interesting to assess the value of histamine and
tryptase levels and whether or not they are correlated with some
systemic symptoms including pruritus, night sweats and/or
weight loss.
In summary, this retrospective study of 59 patients presenting
either a refractory and early relapse cHL (18 cases) or a
responding disease (41 cases), provides evidence that we can
reasonably propose new immunohistochemical markers to
predict the response to treatment of cHL based both on features
of tumoral cells but also on microenvironment. Our immunohis-
tochemical study reveals that in refractory cHL, H/RS cells
present at diagnosis an overexpression of bcl2 marker and a
frequent absence of CD20 expression and that there was an
excess of cytotoxic TiA1+ a n dc k i tp o s i t i v em a s tc e l l s .T h e s e
markers could help to predict at diagnosis the treatment response
of patients with cHL and then to propose new targeted therapies
to refractory patients. However it is likely insufficient to truly
determine wether the immunohistochemical markers are inde-
pendentof known clinical factors becauseof the smallsize sample.
These results warrant further studies on a larger group of cHL by
using micro-arrays technique which could also allow testing other
biological molecules expressed in tumoral cells and in tumoral
background.
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Table 2. Multivariate analysis of immunohistochemical
markers.







CD20 7.55 0.99–57.5 0.04
Bcl2 8.58 1.63–45.1 0.008
TiA1 5.99 1.21–29.7 0.002
c-Kit 2.89 0.61–13.7 0.17
doi:10.1371/journal.pone.0006341.t002
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